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A B S T R A C T
Purpose
The aim of this study was to estimate the contribution of deleterious mutations in the RAD51B,
RAD51C, and RAD51D genes to invasive epithelial ovarian cancer (EOC) in the population and in
a screening trial of individuals at high risk of ovarian cancer.
Patients and Methods
The coding sequence and splice site boundaries of the three RAD51 geneswere sequenced and analyzed
in germline DNA from a case-control study of 3,429 patients with invasive EOC and 2,772 controls as well
as in 2,000 unaffected women who were BRCA1/BRCA2 negative from the United Kingdom Familial
Ovarian Cancer Screening Study (UK_FOCSS) after quality-control analysis.
Results
In the case-control study, we identified predicted deleterious mutations in 28 EOC cases (0.82%)
compared with three controls (0.11%; P  .001). Mutations in EOC cases were more frequent in
RAD51C (14 occurrences, 0.41%) and RAD51D (12 occurrences, 0.35%) than in RAD51B (two
occurrences, 0.06%). RAD51C mutations were associated with an odds ratio of 5.2 (95% CI, 1.1
to 24; P  .035), and RAD51D mutations conferred an odds ratio of 12 (95% CI, 1.5 to 90; P 
.019). We identified 13 RAD51 mutations (0.65%) in unaffected UK_FOCSS participants (RAD51C,
n 7; RAD51D , n 5; and RAD51B, n 1), which was a significantly greater rate than in controls
(P  .001); furthermore, RAD51 mutation carriers were more likely than noncarriers to have a
family history of ovarian cancer (P  .001).
Conclusion
These results confirm that RAD51C and RAD51D are moderate ovarian cancer susceptibility genes
and suggest that they confer levels of risk of EOC that may warrant their use alongside BRCA1 and
BRCA2 in routine clinical genetic testing.
J Clin Oncol 33:2901-2907. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Epithelial ovarian cancer (EOC) has a significant
heritable component. A woman with a single first-
degree relative diagnosed with ovarian cancer has a
three-fold increased riskof thedisease.1,2 Twin stud-
ies suggest thatmost of the familial clustering results
from inherited genetic factors.3 High-penetrance
mutations inBRCA1andBRCA2are associatedwith
the majority of breast-ovarian cancer syndrome
occurrences.4-6 The cumulative estimated risks of
ovariancancer averagedacross all possiblepolygenic
risk modifiers by age 70 years are 36% in BRCA1
carriers and 12% in BRCA2 carriers.7
Other ovarian cancer susceptibility genes include
themismatchrepairgenesMSH6,MSH2, andMLH1,8
which also are associatedwith colorectal and endome-
trial cancers. Several common low-penetrance suscep-
tibility alleles conferring relative risks (RRs)of less than
1.5-fold have been found using genome-wide associa-
tion studies.9-17 The known high-risk susceptibility
genes account for approximately 40% of the excess
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familial riskofEOC,18whereas raremoderate-risk variants andcommon
low-risk variants contribute less than 5%.15 Identification of additional
susceptibility genes that conferRRsgreater than2 coulddecreasemortal-
ity as a result of ovarian cancer through surgical intervention (eg, risk-
reducing salpingo-oophorectomy [RRSO]) in at-risk individuals. Recent
advances in high-throughput next-generation sequencing technologies
have enabled the rapid, targeted analysis of multiple candidate genes in
large populations and have recently identified some novel susceptibility
genes for ovarian cancer, includingRAD51C,19 RAD51D,20 andBRIP1.21
Existing data suggest that the population prevalence of germline muta-
tions in these genes is low, but the published risk estimates (albeit on the
basisof small sample sizes) suggestgenetic testingof thesegenesmayhave
clinical utility. RAD51D mutations were associated with a 6.3-fold in-
crease in risk (95%CI, 2.9 to 14),20 whereasBRIP1mutationswere asso-
ciated with an 8.1-fold increased risk of ovarian cancer (95% CI, 4.7 to
14).21
The aims of this study were to establish the prevalence and pen-
etrance of deleterious mutations in the three interacting double-
strand DNA break repair genes RAD51B, RAD51C, and RAD51D.
PATIENTS AND METHODS
Study Participants
The 3,447 confirmed invasive EOC cases and 2,812 unaffected controls
were from four population-based ovarian cancer case-control studies (AOC
[AustralianOvarianCancer Study],MAL [MalignantOvarianCancer Study],
SEA[StudiesofEpidemiologyandRiskFactors inCancerHeredity], andUKO
[UnitedKingdomOvarianCancer Population Study]), one clinic-based case-
control study (MAYO [Mayo Clinic Ovarian Cancer Study]), one familial
ovarian cancer series of cases andmatched controls from Poland (POC [Poland
ovarian cancer study]), and two familial ovarian cancer registries from theUnited
Kingdom and United States (UKR [United Kingdom Familial Ovarian Cancer
Registry] and GRR [Gilda Radner Familial Ovarian Cancer Registry]). These
studies have been previously described (Table 1 and Appendix Table A1, online
only). Forty-three duplicate samples and four RAD51C mutation–positive con-
trolswere included for quality control.
Also included were 2,000 unaffected participants enrolled onto the
United Kingdom Familial Ovarian Cancer Screening Study (UK_FOCSS).22
Eligible participants were women age 35, with an estimated lifetime risk of
ovarian cancer of  10% on the basis of a family history of ovarian and/or
breast cancer and/or the presence of known predisposing germline gene mu-
tations (BRCA1, BRCA2, and MMR genes) in the family. Volunteers were
recruited between June 2002 and September 2010 from 42 United Kingdom
regional centers. All participants were tested for BRCA1 and BRCA2 muta-
tions, and carriers were excluded from this study.
All studies had approval from the appropriate ethics committee, and all
study participants provided written, informed consent.
Sequencing Library Preparation and Sequencing
We used the 48.48 Fluidigm Access Arrays (Fluidigm, San Francisco,
CA) for target sequence enrichment, asdescribedpreviously8 andaccording to
the manufacturer’s protocol. The RAD51 genes were in a panel of 11 genes
sequenced inSEAandMAYOand inapanelof six genes in the remaining studies.
The results for theothergeneshavebeenreportedpreviously8 or areunpublished.
Fifty-sixprimerpairsweredesigned tocover theexonsandsplice sitesofRAD51B,
RAD51C, and RAD51D (Appendix Table A2, online only) with a combined se-
quencing target of 4 kb.Theprimerdesign achievedgreater than95%coverageof
the target sequence. Sequencing librarieswere quantifiedbyusing aKAPA library
quantificationkit(KapaBiosystems,Boston,MA)withspecificprobesfortheends
of the adapters according to the manufacturer’s protocol. The sequence libraries
were sequencedusing single-end sequencingon the IlluminaGAII (Illumina, San
Diego, CA) or paired end sequencing on the IlluminaHiScan (Illumina) or Illu-
minaHiSeq 2000 (Illumina) according to themanufacturer’s protocol. Each lane
sequenced 384 barcoded samples.
Sequence Data Analysis
Sequenced reads were demultiplexed with standard Illumina software.
Weused theBurrows-WheelerAligner (http://bio-bwa.sourceforge.net/)23 for
sequencing read alignment against the human genome reference sequence
(UCSChg19;University ofCalifornia SantaCruzGenomeReferenceConsor-
tium; http://genome.ucsc.edu/cgi-bin/hgGateway). The Genome Analysis
Toolkit (GATK; https://www.broadinstitute.org/gatk/)24 was used for base
quality-score recalibration, local insertion/deletion (indel) realignment, and
variant (substitution and indel) discovery. Variants were considered only if
they satisfied the set of recommendedGATKfilters, as described in theGATK
best practices guide. ANNOVAR (http://annovar.openbioinformatics.org/
en/latest/)25 was used to annotate the sequence variation detected. We
used PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/bgi.shtml),26 SIFT
(http://sift.bii.a-star.edu.sg/),27 andProvean(http://provean.jcvi.org/protein_
batch_submit.php?specieshuman)28 to predict the function of missense
variants. We used MaxEntScan (http://genetics.bwh.harvard.edu/pph2/
bgi.shtml)29 to predict the pathogenic potential of possible splicing variants in
sequences from 3 base pairs (bp) in the exon to 20 bp in the intron for the 3=
acceptor sites and 3bp in the exon and6bp in the intron for the 5=donor sites.
Variants with a MaxEntScan score that decreased by more than 40% com-
pared with the consensus sequence were assumed to affect splicing.
The alternate allele frequency (Altfreq) for each variant detected in each
samplewasdefinedas the fractionof alternative allele reads comparedwith the
Table 1. Study Patient Cases Sequenced for RAD51B, RAD51C, and RAD51D After Quality-Control Analysis
Study Study Abbreviation No. of Patient Cases No. of Controls Total No. of Participants
On the basis of patients not selected for family history
Australian Ovarian Cancer Study1 AOC 413 428 841
Malignant Ovarian Cancer1 MAL 190 191 381
SEARCH2 SEA 1,259 1,382 2,641
United Kingdom Ovarian Cancer Population Study1 UKO 361 531 892
Mayo Clinic Ovarian Cancer Study2 MAYO 912 146 1,058
Family based
Poland family history, Poland ovarian cancer study1† POC 89 94 183
United Kingdom Familial Ovarian Cancer Registry3† UKR 48 — 48
Gilda Radner Familial Ovarian Cancer Registry3† GRR 157 — 157
Total of all studies 3,429 2,772 6,201
Abbreviation: SEARCH, Studies of Epidemiology and Risk Factors in Cancer Heredity.
Only study not screened for BRCA1/BRCA2 mutations.
†All patient cases had a family history of ovarian cancer.
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total number of reads at that position. We applied thresholds for variant
calling, as defined previously8: With a minimum read depth of 15, alternate
allele heterozygotes were called if the depth was  500 and the Altfreq was
 10%; if the depth ranged from 250 to less than 500 and the Altfreq was
15%; if thedepthranged from30to less than250andtheAltfreqwas20%;
or if the depth ranged from 15 to less than 30 and the Altfreq was  30%.
Samples with fewer than 80% of the target bases covered at a read depth of
15(40controls and18cases)wereexcluded.Wedefineddeleteriousvariants
as those predicted to result in protein truncation (frameshift indels, consensus
splice site substitutions, and nonsense substitutions) or thosemissensemuta-
tions that have been previously reported as deleterious on the basis of in vitro
analysis19,30 or predicted byMaxEntScan to affect splicing.
Ninety percent of the target sequence bases had read depths 15. The
coverage for the three genes is summarized in Appendix Table A2. Concor-
dance for variants called in the 43 duplicate samples was 100%. FourRAD51C
mutation–positive controls also were detected.
Mutation Validation
We visually inspected the sequence alignments for all of the called
deleterious variants by using the Integrative Genomics Viewer (Broad
Institute, Cambridge, MA; https://www.broadinstitute.org/igv/). We
validated all deleterious variants by polymerase chain reaction ampli-
fication and Sanger sequencing.31
Statistical Methods
We tested for an association between deleterious mutations and
ovarian cancer risk by using unconditional logistic regression adjusted
for the country of origin (Australia, Denmark, Poland, the United
Kingdom, and the United States). Odds ratios and associated 95% CIs
also were calculated with data from the case-control studies that were
not family based (AOC, MAL, MAYO, SEA, and UKO).
We estimated the cumulative risk of ovarian cancer with equation 1 by
applying the estimated odds ratio (RR) to population incidence data for
England from 201132:
Cumulative risk  1  ecumulative incidence
See the Data Supplement for a spreadsheet with calculations.
We identifiedmultiple missense variants that have unknown functional
effectson theprotein.Weexcludedallmissensevariants thathadaminorallele
frequency (MAF) of greater than 1% from additional analyses, because large-
scale genome-wide association studies have shown that the RR conferred by a
common susceptibility allele are small (RR 1.3) and thus not detectable by
the smaller sample size of this targeted-sequencing study. The statistical power
to detect single rare alleles by association, even if they confer larger risk (RR
2), is still modest. Therefore, we used the rare admixture likelihood (RAML)
burden test33 to test for an associationonagene-by-genebasis. TheRAMLtest
combines the data for multiple variants and allows for alleles associated with
either an increased or a decreased risk. We classified variants with anMAF
1% into three groups: deleterious variants as defined previously (these were
excluded from the RAML analyses); variants predicted to have a damaging
effect on protein function by at least two of three prediction tools (SIFT [score
0.05], PolyPhen-2 [classified as probably damaging/damaging], and Provean
[score2.5]);andvariantswithprobablebenigneffects.Onlypatientswhohad
a call rate greater than 80% formissense variants and variants that had a call rate
greater than 80% and genotype frequencies consistent with theHardy-Weinberg
equilibrium (P 105)were included in these analyses.
RESULTS
Deleterious RAD51B, RAD51C, and RAD51D Mutations
in Ovarian Cancer Cases and Controls
Sequencedata for thecoding regionsandsplice siteboundariesof
RAD51B, RAD51C, and RAD51D were available for 3,429 invasive
EOC cases and 2,772 controls after quality control (Table 1). We
identified 135 unique variants, of which eight (5.9%) were frameshift
indels, 10 (7.4%) were nonsense substitutions, five (3.7%) were pre-
dicted splice site alterations, and 113 (78%) were missense substitu-
tions. Of the 113 missense variants, one (RAD51C 428AG) was
deleterious,30 105 had anMAF less than 1%, and seven (5.1%) had an
MAF greater than 1%.
We identifieddeleteriousmutations in two cases forRAD51B, 14
cases and two controls for RAD51C, and 12 cases and one control for
RAD51D.Of these, 23 deleteriousmutation carriers were identified
in 3,135 cases (0.73%) unselected for family history (Table 2 and
Appendix Table A3, online only). One case had two deleterious
mutations close to each other and in cis (G217X and Q219X) in
RAD51D. The prevalence of deleterious mutations was signifi-
cantly higher (P  .001) in cases (28 of 3,429; 0.82%) than in
controls (three of 2,772; 0.11%). Eight deleterious mutations were
detected in more than one individual. Three of these (RAD51C
732delT and A428G and RAD51D C898T) were identified in a case
and a control. Of the 29 predicted deleterious variants in cases, 22
(76%) were frameshift indels or nonsense variants, six (21%) were
splice site substitutions, and one (3.4%) was a missense variant
previously reported as deleterious.30
We also evaluated the prevalence of RAD51B, RAD51C, and
RAD51D variants in 2,000 individuals from UK_FOCSS. We
identified 149 unique variants, of which three (2.0%) were
frameshift indels, three (2.0%) were nonsense substitutions,
two (1.3%) were predicted splice site alterations, and 141 (95%)
were missense substitutions. Thirteen participants carried one
of the eight different deleterious mutations in one of these genes
(one in RAD51B, seven in RAD51C, and five in RAD51D). The
overall prevalence (0.65%) was significantly greater than that of
the general population controls (P  .001; Table 3).
Ovarian Cancer Risks Associated With RAD51B,
RAD51C, and RAD51D Mutations
The odds ratio (adjusted for country of origin) associated with a
deleteriousmutation in any of the three genes was 8.1 (95%CI, 2.4 to
27;P .001) forall ovariancancer subtypesand9.3 (95%CI,2.7 to32;
P .001) for the serous subtype. Gene-specific odds ratios (adjusted
for country of origin) for all ovarian cancer subtypes were 5.2 for
RAD51C (95%CI, 1.1 to 24; P .035) and 12 for RAD51D (95%CI,
1.5 to 90; P .019). Gene-specific odds ratios for the serous subtype
were7.4 forRAD51C (95%CI,1.6 to35;P .011)and12 forRAD51D
Table 2.Mutation Carriers Identified in RAD51B, RAD51C, and RAD51D in
Ovarian Cancer Patient Cases and Controls
Mutation
Carrier Status
Controls
Patient Cases
All
Unselected for
Family History
No. % No. % No. %
Noncarrier 2,769 99.9 3,401 99.2 3,112 99.3
Mutation carrier
Any mutation 3 0.11 28 0.82 23
RAD51B 0 0 2 0.06 2 0.06
RAD51C 2 0.07 14 0.41 10 0.32
RAD51D 1 0.04 12 0.35 11 0.35
One patient case carried two deleterious mutations.
Germline Mutations in RAD51 Genes and Ovarian Cancer
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(95%CI, 1.5 to 97; P .021). The estimated average cumulative risks
of ovarian cancer by age 50 were 1.3% (95% CI, 0.3% to 6.0%) for
RAD51C and 3.0% (95% CI, 0.4% to 21%) for RAD51D. The equiv-
alent risks by age 70 were 5.2% (95% CI, 1.1% to 22%) for RAD51C
and 12% (95%CI, 1.5% to 60%) for RAD51D.
Clinicopathologic Characteristics Associated With
RAD51B, RAD51C, and RAD51D Mutations
The clinical and histopathologic characteristics of all pa-
tient cases are listed in Appendix Table A1. Mutation carriers
were more likely than noncarriers to have high-grade serous
versus other histologic subtypes (P  .046; Table 4). Eighteen
percent of mutation carriers were diagnosed at ages 40 to 49
years, and no mutation carrier was diagnosed with ovarian
cancer before age 40 years (Table 4). Carriers of a mutation in
any of the RAD51 genes were more likely than noncarriers to
have a family history of ovarian cancer, although this difference
was not statistically significant (24% v 14%; P  .16 for all
genes). The proportion of RAD51C mutation carriers with a
family history was higher (36%; P .021; Table 5). In UK_FO-
CSS participants, mutation carriers were also more likely than
noncarriers to be associated with a family history of ovarian
cancer (Table 3); 9 of 13 mutation carriers (69%) compared
with 548 of 1,987 noncarriers (28%) had a family history com-
prising two or more ovarian cancer cases in first- or second-
degree relatives (P  .001).
RAD51B, RAD51C, and RAD51D Missense Variants
and Ovarian Cancer Risk
We used three bioinformatics tools (SIFT, PolyPhen-2, and
Provean) to predict the effects on protein function of 112 missense
variants. Thirty missense variants were classified as deleterious by all
three tools, 12 missense variants by at least two of three tools, and 15
variants by one of three tools; 55 missense variants were predicted to
be neutral by all three tools (Appendix Table A4). For the 38missense
variantswithanMAF1%andpredictedbyat least twoof three tools
to have a functional effect, we compared the relative burden in cases
and controls for each gene with the RAML test.33 We found some
evidence for an association of the rare missense variation in RAD51C
with an increased riskof ovarian cancer for all ovarian cancer subtypes
(RAML testP .029), and the effectwas stronger for the serous subtype
(RAMLtestP .001).Wealso found someevidenceof an associationof
missense variants in RAD51D with an increased risk of serous ovarian
cancer (P  .012). There was little evidence of an association of rare
missense variants in RAD51B and RAD51D with all ovarian cancer sub-
types or inRAD51Bwith serous ovarian cancer (P .05).
Table 3. Characteristics of the United Kingdom Familial Ovarian Cancer Screening Study Mutation Carriers
Gene
Mutation Information Proband Characteristic
Family History
No. of Affected
First-Degree
Relatives
No. of Affected
First- and Second-
Degree Relatives
cDNA
Change Location
Protein
Change Predicted Effect
Ref. Age,
Years
Breast Cancer
(age in years)
Ovarian
Cancer
Breast
Cancer
Ovarian
Cancer
Breast
Cancer
RAD51B 854-2AG Intron 8 NA Splicing 58 No 0 0 2 0
RAD51C C97T Exon 1 Q33X Nonsense 31 No 1 1 2 1
RAD51C 158delC Exon 2 S53fs Frameshift deletion 69 No 2 0 2 0
RAD51C C577T Exon 4 R193X Nonsense 46 No 0 0 0 1
RAD51C C577T Exon 4 R193X Nonsense 46 No 1 0 2 0
RAD51C C577T Exon 4 R193X Nonsense 41 No 1 0 2 0
RAD51C 731delT Exon 5 I244fs Frameshift deletion 51 No 1 0 3 0
RAD51C 731delT Exon 5 I244fs Frameshift deletion 64 Yes (57) 2 0 3 1
RAD51D 263  1GA Intron 3 NA Splicing 53 No 1 0 4 0
RAD51D C556T Exon 6 R186X Nonsense 62 No 1 0 3 2
RAD51D C556T Exon 6 R186X Nonsense 62 Yes (52) 1 0 1 1
RAD51D C556T Exon 6 R186X Nonsense 25 No 1 0 1 0
RAD51D 748delC Exon 9 H250fs Frameshift deletion 50 No 1 0 1 1
Abbreviation: Ref., reference.
Table 4.Mutation Status by Age at Disease Onset and Histologic Subtype in Patient Cases With Ovarian Cancer
Mutation Status
No. (%) of Patients by Age at Diagnosis, Years Histology, No. (%)
 40 40-49 50-59  60 Unknown High-Grade Serous Other
Noncarrier (n  3,401) 165 (4.9) 514 (15) 1,073 (32) 1,642 (48) 7 (0.2) 1,786 (53) 1,615 (47)
Mutation carrier (n  28) 0 5 (18) 11 (39) 12 (43) 0 20 (71) 8 (29)
RAD51B (n  2) 0 0 0 2 (100) 0 1 (50) 1 (50)
RAD51C (n  14) 0 4 (29) 5 (36) 5 (36) 0 10 (71) 4 (29)
RAD51D (n  12) 0 1 (8.3) 6 (50) 5 (42) 0 9 (75) 3 (25)
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DISCUSSION
To our knowledge, this study is the largest population-based ovar-
ian cancer study to date to estimate the prevalence of mutations in
theRAD51B,RAD51C, andRAD51D genes. Overall, 0.81%of EOC
cases had a mutation in one of these three genes compared with
0.11% in controls. Our data suggest that both RAD51C and
RAD51D are ovarian cancer susceptibility genes; however,
RAD51B mutations are unlikely to contribute substantially to
ovarian cancer risk.
Several other studies have reported on the prevalence of germ-
line genetic variations in these genes (Appendix Table A5). How-
ever, for most of these, the ascertainment of cases was complex:
several sequenced an affected proband (either breast or ovarian
cancer) from a family with multiple cases of breast and/or ovarian
cancer. Six studies sequenced RAD51C in ovarian cancer cases
unselected for family history,34-39 but only one of these carried out
equivalent sequencing of controls.34 Three studies sequenced
RAD51D in unselected ovarian cancer cases,36,40,41 but none of
these sequenced the whole gene in controls. In these studies, the
mutation frequency in cases ranged from 0.4% to 1.1% for
RAD51C and 0.8% to 1.1% for RAD51D.
In this study, the mutation frequency in cases unselected for
family history was 0.32% for RAD51C and 0.35% in RAD51D. These
are likely to be underestimates of the true mutation frequencies. Our
next-generation sequencing approach enabled rapid and high-
throughput analysis of candidate genes in thousands of samples but
did not provide complete coverage of all genes in all samples (mean
coverage per sample, 90%). Also, we used polymerase chain reaction–
based enrichment of candidate gene coding regions; any deleterious
mutations occurring outside these regions (eg, large genomic dele-
tions and rearrangements) would not have been detected. Finally, we
didnot includemissense variants in our prevalence estimates, because
we could not be certain of their pathogenicity in the absence of
definitive functional assays. However, burden tests for RAD51C
and RAD51D variants indicate that rare missense variants that are
predicted to disrupt protein function are significantly more prev-
alent in cases than controls, which suggests that at least a propor-
tion of these variants is deleterious.
High-grade serous ovarian cancer (HGSOC) is the most com-
mon ovarian cancer subtype, and mutations were more prevalent
in patients with HGSOC (1.1%) than in other subtypes (0.49%).
This finding, perhaps, is expected, because deficiency of double-
strandDNAbreak repair by homologous recombination as a result
of germline mutations in BRCA1 or BRCA2 also is associated with
HGSOC.8,42
Although there are similarities in the functional mechanisms
associated with the RAD51 genes and BRCA1/BRCA2, the genetic
epidemiology suggests there are also differences. For example,
BRCA1 and BRCA2 mutations confer risks of both breast and
ovarian cancer, but there is little evidence from other studies that
RAD51C or RAD51D mutations confer increased risks of breast
cancer. The location of truncating mutations in BRCA1/BRCA2 is
associated with variable risks of breast and ovarian cancer.43,44 All
except two of the predicted truncating mutations identified in
RAD51C were located between amino acid 143 and 319 in a func-
tional domain in the C terminus of the protein (residues 79 to
376).45 This domain is important for forming the RAD51B-
RAD51C-RAD51D-XRCC2 and RAD51C-XRCC3 complexes.
Likewise, all of the deleterious mutations identified in RAD51D
were clustered in the C-terminal region (residues 77 to 328), which
affects binding to RAD51C and likely impairs double-strand DNA
break repair45 (Fig 1).
Our RR estimate for RAD51D is similar to that reported previ-
ously by Loveday et al20 (6.3; 95% CI, 2.9 to 14) on the basis of the
analysis of families with multiple cases of ovarian cancer. Our RR
estimate forRAD51C is similar to those reportedbyPelttari et al35 (6.3;
95%CI, 1.2 to 35) for unselected ovarian cancer. The wide CIs of risk
estimates for both genes suggest that caution needs to be applied if the
genesareusedclinically forgenetic riskprediction. Inaddition, the fact
that 18% of ovarian cancers in women carrying RAD51C and
Table 5.Mutation Status by First Degree of Family History of Breast and/or
Ovarian Cancer in Patient Cases With Ovarian Cancer
Gene
No. (%) of Patient Cases by Family History
No FH
(n  2,307)
OvFH Only
(n  430)
BrFH Only
(n  467)
BrOvFH
(n  29)
Noncarrier 2,292 (71) 424 (13) 463 (14) 29 (0.90)
Mutation carrier
Any 15 (60) 6 (24) 4 (16) 0
RAD51B 1 (100) 0 0 0
RAD51C 6 (43) 5 (36) 3 (21) 0
RAD51D 8 (80) 1 (10) 1 (10) 0
Abbreviations: BrFH, first degree of family history of breast cancer; BrOvFH,
first degree of family history of both ovarian and breast cancer; no FH, no first
degree of family history of breast or ovarian cancer; OvFH, first degree of
family history of ovarian cancer.
150 bp
RAD51B exons
2 3 4 5 6 7 8 9 10 11
RAD51C exons
2* 2 2 2*
987654321
RAD51D exons
*22 2 2
2 3 4 5 6 7 8 9 101
Fig 1. Distribution of predicted delete-
rious variants in RAD51B, RAD51C, and
RAD51D. The location of each mutation is
shown in the exon structure of the coding
sequence. Mutations occurring in multiple
individuals are indicated with the number
of carriers above the small balloon. Coding
regions of all the genes are on the same
scale. (*) Deleterious mutation identified
(one each in case and control groups).
bp, base pair.
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RAD51D mutations occurred at younger than 50 years (Table 4)
suggests that, if risk estimates were confirmed, offering premeno-
pausal women the option of RRSO should be considered. If clinical
testing for RAD51C and RAD51D was approved, women could un-
dergo panel testing for multiple susceptibility genes, and carriers,
along with their relatives, could be offered RRSO.
In summary, we estimate that RAD51B, RAD51C, and RAD51D
are responsible for approximately one in every 90 high-grade serous
EOCoccurrences and one in every 120 EOCoccurrences. In addition
to the benefit ofmutation testing ofRAD51C andRAD51D for disease
prevention, mutation carriers also may be responsive to treatment
with poly(ADP-ribose) polymerase inhibitors, which results in syn-
thetic lethality of cells that have mutant homologous recombination
or double-strand DNA break repair. This treatment might improve
progression-free survival among these patients. Hence, such testing
may be useful in patient decisionmaking.
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GLOSSARY TERMS
allele: an alternative form of a gene (in diploids, one member
of a pair) that is located at a specific position on a specific
chromosome.
missensemutation: a change (mutation) in one nucleotide
that results in the coding of a different amino acid.
penetrance: the likelihood that a given gene mutation will produce
disease. This likelihood is calculated by examining the proportion of
people with the particular genetic mutation that show symptoms of
disease.
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Appendix
Table A1. Characteristics of the Patients With Ovarian Cancer
Characteristic
No. (%) of Patients by Study
No. (%) of
Total Patients
(N  3,429)
AOC
(n  413)
GRR
(n  157)
MAL
(n  190)
MAYO
(n  912)
POC
(n  89)
SEA
(n  1,259)
UKR
(n  48)
UKO
(n  361)
Mean (range) age at
diagnosis,
years 60.1 (23-79) 49.4 (21-83) 61.7 (38-80) 62.5 (23-91) 51.1 (21-77) 56.0 (19-74) 53.0 (24-77) 61.2 (25-90) 58.7 (19-91)
Morphology
High-grade
serous 359 (87) 54 (34) 137 (72) 654 (72) 26 (29) 341 (27) 17 (35) 266 (74) 1,806 (53)
Low-grade
serous 24 (5.8) 6 (3.8) 18 (9.5) 26 (2.9) 5 (5.6) 275 (22) 2 (4.2) 21 (5.8) 405 (12)
Serous 14 (3.4) 34 (22) 12 (6.3) 0 10 (11) 0 6 (13) 58 (16) 151 (4.4)
Endometrioid 3 (0.73) 19 (12) 13 (6.8) 110 (12) 13 (15) 214 (17) 5 (10) 6 (1.7) 383 (11)
Clear cell 3 (0.73) 12 (7.6) 6 (3.2) 55 (6.0) 1 (1.1) 144 (11) 2 (4.2) 2 (0.55) 225 (6.6)
Mucinous 2 (0.48) 8 (5.1) 2 (1.1) 25 (3.7) 9 (10) 116 (9.2) 3 (6.3) 1 (0.28) 166 (4.8)
Mixed 6 (1.5) 2 (1.3) 0 31 (3.4) 1 (1.1) 70 (5.6) 1 (2.1) 5 (1.4) 116 (3.4)
Other 1 (0.24) 21 (13) 0 11 (1.2) 24 (27) 79 (6.3) 11 (23) 2 (0.55) 152 (4.4)
Undifferentiated 1 (0.24) 1 (0.64) 2 (1.1) 0 0 20 (1.6) 1 (2.1) 0 25 (0.73)
Unknown 359 (87) 54 (34) 137 (72) 654 (72) 26 (29) 341 (27) 17 (35) 266 (74) 1,806 (53)
Stage
1 17 (4.1) 0 10 (5.3) 141 (15) 3 (3.4) 442 (35) 2 (4.2) 27 (7.5) 642 (19)
2 35 (8.5) 0 31 (16) 51 (5.6) 2 (2.3) 115 (9.1) 2 (4.2) 71 (20) 307 (9.0)
3 359 (87) 0 149 (78) 709 (78) 9 (10) 431 (34) 9 (19) 244 (67) 1,910 (56)
Unknown 2 (0.48) 157 (100) 0 11 (1.2) 75 (84) 271 (22) 35 (73) 19 (5.3) 570 (17)
Grade
Low 28 (6.8) 18 (11) 42 (22) 128 (14) 12 (13) 411 (33) 7 (15) 24 (6.6) 670 (20)
High 370 (90) 74 (47) 135 (71) 754 (83) 41 (46) 670 (53) 28 (58) 275 (76) 2,347 (68)
Unknown 15 (3.6) 65 (41) 13 (6.8) 30 (3.3) 36 (40) 178 (14) 13 (27) 62 (17) 412 (15)
Abbreviations: AOC, Australian Ovarian Cancer Study; GRR, Gilda Radner Familial Ovarian Cancer Registry; MAL, Malignant Ovarian Cancer Study; MAYO, Mayo
Clinic Ovarian Cancer Study; POC, Poland Ovarian Cancer Study; SEA, Studies of Epidemiology and Risk Factors in Cancer Heredity; UKO, United Kingdom Ovarian
Cancer Population Study; UKR, United Kingdom Familial Ovarian Cancer Registry.
Stages were defined as follows: 1, localized; 2, regional; and 3, distant.
Table A2. Sequencing Coverage by Gene
Gene Accession No.
No. of Coding
Exons
Total Coding
Length (bp)
No. of Amplicons
Designed
% Coding Sequence
Covered by Design
Mean % Sequence Covered
by Read Depth  15
RAD51B NM_133509 10 1,389 23 97 85
RAD51C NM_058216 9 1,339 19 97 93
RAD51D NM_002878 10 1,221 14 95 90
Abbreviation: bp, base pair.
The sequence also contains 20 bp in the intron for the 3= acceptor sites and 6 bp in the intron for the donor 5= sites.
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Table A3. Predicted Deleterious Mutations Found in RAD51B, RAD51C, and RAD51D
Study and
Patient Group Gene cDNA Change Location Protein Change Predicted Function
Ref. Age,
Years
Ovarian
Cancer
FH1
Breast
Cancer
FH1
Grade
Group
Histology
Group
Control
SEA RAD51C 428AG Exon 3 Q143R Missense 51 0 0
SEA RAD51C 732delT Exon 5 I244fs Frameshift deletion 56 0 0
AOC RAD51D 898CT Exon 9 R300X Nonsense 49 0 1
Patient case
AOC RAD51B 489TG Exon 6 Y163X Nonsense 62 2 Serous HG
SEA RAD51B 957GC Exon 9 Q319H Splicing 61 0 0 2 Other
SEA RAD51C 428AG Exon 3 Q143R Missense 49 0 0 1 Serous LG
MAL RAD51C 498delT Exon 3 V166fs Frameshift deletion 52 0 0 2 Serous HG
SEA RAD51C 572-1GT Intron 3 Splicing 54 0 0 2 Serous HG
POC RAD51C 577CT Exon 4 R193X Nonsense 60 Other
POC RAD51C 577CT Exon 4 R193X Nonsense 41 1 2 Serous HG
AOC RAD51C 653_654del Exon 4 218_218del Frameshift deletion 64 0 0 2 Serous HG
UKO RAD51C 706-2AG Intron 4 Splicing 65 1 0 2 Serous HG
UKR RAD51C 706-2AG Intron 4 Splicing 50 1 2 Serous HG
SEA RAD51C 732delT Exon 5 I244fs Frameshift deletion 48 0 0 2 Serous HG
MAYO RAD51C 774delT Exon 5 R258fs Frameshift deletion 55 0 1 2 Clear cell
POC RAD51C 905-2delAG Intron 6 Splicing 52 1 Endometrioid
AOC RAD51C 955CT Exon 7 R319X Nonsense 74 0 1 2 Serous HG
AOC RAD51C 955CT Exon 7 R319X Nonsense 40 0 1 2 Serous HG
SEA RAD51C 97CT Exon 1 Q33X Nonsense 61 0 0 2 Serous HG
UKR RAD51D 478CT Exon 5 Q160X Nonsense 56 1 0 2 Serous HG
MAL RAD51D 564_567del Exon 6 188_189del Frameshift deletion 59 2 Serous HG
MAL RAD51D 564_567del Exon 6 188_189del Frameshift deletion 76 2 Serous HG
SEA RAD51D 564delT Exon 6 T188fs Frameshift deletion 59 0 0 2 Serous HG
SEA RAD51D 576  1GA Intron 6 Splicing 66 0 0 2 Endometrioid
UKO RAD51D 620CA Exon 7 S207X Nonsense 59 0 0 2 Serous HG
SEA RAD51D 623dupT Exon 7 V208fs Frameshift insertion 54 0 1 2 Serous HG
MAYO RAD51D 655CT/649GT Exon 7 G217X/Q219X Nonsense 73 0 0 2 Serous HG
SEA RAD51D 741_742insTG Exon 9 T248_N249delinsX Nonsense 56 0 0 2 Endometrioid
SEA RAD51D 748delC Exon 9 H250fs Frameshift deletion 67 0 0 2 Serous HG
SEA RAD51D 748delC Exon 9 H250fs Frameshift deletion 47 0 0 2 Serous HG
SEA RAD51D 898CT Exon 9 R300X Nonsense 62 0 0 2 Endometrioid
Abbreviations: AOC, Australian Ovarian Cancer Study; GRR, Gilda Radner Familial Ovarian Cancer Registry; MAL, Malignant Ovarian Cancer Study; MAYO, Mayo
Clinic Ovarian Cancer Study; POC, Poland Ovarian Cancer Study; SEA, Studies of Epidemiology and Risk Factors in Cancer Heredity; Serous HG, high-grade serous;
Serous LG, low-grade serous; UKO, United Kingdom Ovarian Cancer Population Study; UKR, United Kingdom Familial Ovarian Cancer Registry.
First degree of family history.
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Table A4. Catalog of Missense Mutations Found in RAD51B, RAD51C, and RAD51D
Gene and Variant Type Chromosome Position cDNA Exon Protein SIFT PolyPhen-2† Provean‡ Score§
No. of
Controls
No. of Patient
Cases¶
Common variant (MAF  1%; n  7)
RAD51B 14 68352648 515TG Exon 6 L172W 1 1 0 2 64 69
RAD51B 14 68353893 728AG Exon 7 K243R 1 1 0 2 57 82
RAD51B 14 69061259 1094CG Exon 11 P365R 0 1 0 1 119 148
RAD51C 17 56772522 376GA Exon 2 A126T 0 0 0 0 31 37
RAD51C 17 56798128 859AG Exon 6 T287A 1 1 1 3 44 63
RAD51D 17 33433487 494GA Exon 6 R165Q 0 0 0 0 536 780
RAD51D 17 33430313 698AG Exon 8 E233G 0 1 1 2 90 124
Potentially deleterious rare variant (n  38)#
RAD51B 14 68331751 347AG Exon 5 Q116R 1 1 1 3 0 1
RAD51B 14 68331826 422TA Exon 5 I141N 1 1 1 3 1 0
RAD51B 14 68331829 425AG Exon 5 D142G 1 1 1 3 1 0
RAD51B 14 68352608 475CT Exon 6 R159C 1 1 1 3 0 2
RAD51B 14 68352609 476GA Exon 6 R159H 1 1 1 3 0 1
RAD51B 14 68352686 553TG Exon 6 C185G 0 1 1 2 1 1
RAD51B 14 68353814 649AG Exon 7 R217G 1 1 1 3 0 1
RAD51B 14 68878170 883GA Exon 9 A295T 1 1 1 3 0 1
RAD51B 14 68878171 884CT Exon 9 A295V 1 0 1 2 1 0
RAD51C 17 56770081 77AT Exon 1 K26M 1 1 1 3 0 1
RAD51C 17 56770084 80TC Exon 1 L27P 1 1 1 3 0 1
RAD51C 17 56772417 271CT Exon 2 L91F 1 1 1 3 0 1
RAD51C 17 56772481 335GT Exon 2 G112V 1 1 1 3 0 1
RAD51C 17 56772540 394AC Exon 2 T132P 1 1 1 3 0 1
RAD51C 17 56772543 397CA Exon 2 Q133K 1 1 1 3 0 1
RAD51C 17 56774068 419TG Exon 3 V140G 1 1 1 3 0 1
RAD51C 17 56774134 485GA Exon 3 G162E 1 1 1 3 1 0
RAD51C 17 56774146 497TG Exon 3 V166G 1 0 1 2 0 1
RAD51C 17 56780662 677TC Exon 4 L226P 1 1 1 3 0 1
RAD51C 17 56787260 746GA Exon 5 R249H 0 1 1 2 1 0
RAD51C 17 56787349 835GC Exon 5 A279P 1 1 1 3 0 1
RAD51C 17 56809885 1006AC Exon 8 T336P 1 0 1 2 0 1
RAD51D 17 33446607 26GC Exon 1 C9S 1 0 1 2 2 5
RAD51D 17 33445598 185CT Exon 3 S62L 1 0 1 2 1 0
RAD51D 17 33445581 202GA Exon 3 G68S 1 1 1 3 0 1
RAD51D 17 33434138 349TA Exon 5 C117S 1 1 1 3 0 1
RAD51D 17 33434081 406GC Exon 5 D136H 1 1 1 3 0 1
RAD51D 17 33433490 491TC Exon 6 L164P 1 1 1 3 0 1
RAD51D 17 33433488 493CT Exon 6 R165W 1 1 1 3 1 0
RAD51D 17 33433448 533TG Exon 6 M178R 1 0 1 2 1 1
RAD51D 17 33430511 629CT Exon 7 A210V 1 1 1 3 0 2
RAD51D 17 33430487 653GA Exon7 G218D 1 1 1 3 0 1
RAD51D 17 33430296 715CT Exon 8 R239W 1 1 1 3 0 1
RAD51D 17 33428338 785CT Exon 9 P262L 1 1 1 3 0 1
RAD51D 17 33428330 793GA Exon 9 G265R 1 1 1 3 2 0
RAD51D 17 33428309 814CT Exon 9 P272S 1 1 1 3 1 0
RAD51D 17 33428300 823CT Exon 9 R275W 1 1 1 3 0 1
RAD51D 17 33428015 944GA Exon 10 G315E 1 0 1 2 1 0
Probably benign rare variant (n  67)
RAD51B 14 68290285 25GA Exon 2 V9M 0 0 0 0 1 0
RAD51B 14 68290324 64CT Exon 2 H22Y 0 0 0 0 0 1
RAD51B 14 68292196 100TC Exon 3 S34P 0 1 0 1 1 0
RAD51B 14 68292283 187AG Exon 3 K63E 0 0 0 0 1 1
RAD51B 14 68301803 205GA Exon 4 G69R 0 0 0 0 2 0
RAD51B 14 68301820 222GT Exon 4 R74S 0 0 1 1 1 0
RAD51B 14 68301824 226GA Exon 4 A76T 0 0 0 0 0 1
RAD51B 14 68301830 232TC Exon 4 F78L 0 0 0 0 0 1
RAD51B 14 68301863 265GA Exon 4 A89T 0 0 0 0 0 1
RAD51B 14 68301872 274GA Exon 4 E92K 0 0 0 0 1 1
RAD51B 14 68301894 296CT Exon 4 A99V 1 0 0 1 0 1
(continued on following page)
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Table A4. Catalog of Missense Mutations Found in RAD51B, RAD51C, and RAD51D (continued)
Gene and Variant Type Chromosome Position cDNA Exon Protein SIFT PolyPhen-2† Provean‡ Score§
No. of
Controls
No. of Patient
Cases¶
RAD51B 14 68331763 359TC Exon 5 M120T 0 0 0 0 1 0
RAD51B 14 68331840 436GA Exon 5 A146T 0 1 0 1 1 1
RAD51B 14 68352659 526AG Exon 6 K176E 1 0 0 1 1 0
RAD51B 14 68352672 539AG Exon 6 Y180C 0 0 0 0 20 39
RAD51B 14 68353784 619GT Exon 7 V207L 0 0 0 0 17 22
RAD51B 14 68353913 748TG Exon 7 S250A 0 0 0 0 0 2
RAD51B 14 68878147 860CA Exon9 S287Y 1 0 0 1 0 1
RAD51B 14 68878180 893AG Exon 9 N298S 0 1 0 1 0 1
RAD51B 14 68878224 937CG Exon 9 L313V 0 0 0 0 0 1
RAD51B 14 68934949 1018GC Exon 10 E340Q 0 0 0 0 2 0
RAD51B 14 68934959 1028TC Exon 10 V343A 0 0 0 0 0 1
RAD51B 14 69061225 1060CG Exon 11 Q354E 0 0 0 0 1 0
RAD51B 14 69061226 1061AC Exon 11 Q354P 0 0 0 0 1 0
RAD51B 14 69061228 1063GA Exon 11 A355T 0 0 0 0 13 21
RAD51C 17 56770011 7GA Exon 1 G3R 0 0 0 0 0 1
RAD51C 17 56770018 14CT Exon 1 T5M 1 0 0 1 1 0
RAD51C 17 56770036 32AG Exon 1 Q11R 0 0 0 0 0 1
RAD51C 17 56770131 127CT Exon 1 P43S 0 0 1 1 0 1
RAD51C 17 56772345 199GA Exon 2 E67K 0 0 0 0 0 1
RAD51C 17 56772359 213TA Exon 2 N71K 0 0 0 0 1 0
RAD51C 17 56772390 244CA Exon 2 H82N 0 0 0 0 0 1
RAD51C 17 56772398 252GT Exon 2 K84N 0 0 0 0 0 1
RAD51C 17 56772504 358AG Exon 2 T120A 0 0 0 0 1 0
RAD51C 17 56774057 408GA Exon 3 M136I 0 0 0 0 1 0
RAD51C 17 56774080 431TC Exon 3 I144T 0 0 1 1 1 0
RAD51C 17 56774142 493AT Exon 3 M165L 0 0 0 0 1 2
RAD51C 17 56774155 506TC Exon 3 V169A 0 0 0 0 1 0
RAD51C 17 56774158 509TG Exon 3 V170G 0 0 1 1 1 1
RAD51C 17 56774170 521CG Exon 3 T174S 0 0 0 0 0 1
RAD51C 17 56774214 565GA Exon 3 G189R 0 0 0 0 0 1
RAD51C 17 56780592 607AG Exon 4 N203D 0 0 0 0 0 1
RAD51C 17 56780605 620AG Exon 4 H207R 0 0 0 0 0 1
RAD51C 17 56787298 784TG Exon 5 L262V 0 0 0 0 1 4
RAD51C 17 56787304 790GA Exon 5 G264S 0 0 1 1 19 23
RAD51C 17 56798141 872AT Exon 6 D291V 0 0 0 0 1 0
RAD51C 17 56801448 952GA Exon 7 D318N 0 0 0 0 0 1
RAD51C 17 56801452 956GA Exon 7 R319Q 0 0 0 0 1 1
RAD51C 17 56811513 1061CT Exon 9 A354V 0 0 0 0 0 1
RAD51C 17 56811542 1090AG Exon 9 S364G 0 0 0 0 1 0
RAD51D 17 33446566 67CT Exon 1 H23Y 0 0 0 0 1 1
RAD51D 17 33446143 131GA Exon 2 G44D 0 0 0 0 0 1
RAD51D 17 33446143 131GC Exon 2 G44A 0 0 0 0 0 1
RAD51D 17 33445575 208GA Exon 3 D70N 0 0 1 1 0 1
RAD51D 17 33434132 355TC Exon 5 C119R 0 0 0 0 2 2
RAD51D 17 33434093 394GA Exon 5 V132I 1 0 0 1 0 2
RAD51D 17 33433451 530AG Exon 6 Q177R 0 0 0 0 2 0
RAD51D 17 33433447 534GC Exon 6 M178I 0 0 0 0 1 0
RAD51D 17 33433446 535CG Exon 6 L179V 0 0 0 0 0 1
RAD51D 17 33433413 568GA Exon 6 A190T 0 0 0 0 0 2
RAD51D 17 33428370 753AG Exon 9 I251M 0 0 0 0 0 1
RAD51D 17 33428279 844GA Exon 9 E282K 0 0 0 0 0 1
RAD51D 17 33428261 862GC Exon 9 G288R 0 0 0 0 0 1
RAD51D 17 33428251 872GA Exon 9 R291H 0 0 0 0 1 0
RAD51D 17 33428245 878CT Exon 9 A293V 0 0 0 0 1 0
RAD51D 17 33428037 922AG Exon 10 M308V 0 0 0 0 0 1
RAD51D 17 33428022 937AG Exon 10 T313A 0 0 0 0 1 0
SIFT: 0, tolerated; 1, not tolerated.
†PolyPhen-2: 0, benign/possibly damaging; 1, probably damaging.
‡Provean: 0, neutral; 1, deleterious.
§Score: number of algorithms (SIFT/PolyPhen-2/Provean) that predict deleterious effect of the missense variant.
No. of times the variant was identified in controls.
¶No. of times the variant was identified in controls.
#At least two of three prediction algorithms predict deleterious effect on protein function.
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Table A5. Reported Targeted Sequencing on RAD51 Genes
Study and Location by Gene
No. of Patients Analyzed No. (%) of RAD51 Mutations Identified
Total BC BC/OC OC uOC Controls Total BC BC/OC OC uOC Controls
RAD51C
Germany19 1,100 620 480 0 0 480  2,432† 6 (0.5) 6 (1.25) 0 0 0
Untied States (Zheng et al)‡ 92 0 92 0 0 0 0 0 0 0 0 0
Canada (Akbari et al)‡ 454 NS NS NS 0 0 0 NS NS NS 0
Finland35 2,747 130  2,061† 139 8 409† 2,086† 8 (0.3) 0 2 (1.4) 2 (25) 4† (1.0) 2† (0.1)
Finland and Sweden38 1,704 1,105† 35 0 232  332† 871† 2 (0.1) 0 1 (2.8) 0 1 (0.4)  0† 0†
United States (Clague et al)‡ 286 133 34 119 0 0 0 0 0 0 0 0
Australia37 1,655 1,053 314 21 267 427 3 (0.2) 0 1 (0.3) 1 (4.8) 1 (0.4) 0
The Netherlands and Canada
(De Leeneer et al)‡ 351 0 239 112 0 0 0 0 0 0 0 0
Spain30 785 485 300 0 0 500 5 (0.6) 1 (0.2) 4 (1.3) 0 0 0
United States (Lu et al)‡ 192 157 35 0 0 0 0 0 0 0 0 0
United Kingdom34 1,404 0 1,102 30 272 1,156 12 (0.9) 0 8 (0.7) 1 (3.3) 3 (1.1) 1 (0.09)
France (Coulet et al)‡ 117 0 82 35 0 0 3 (2.6) 0 2 (2.4) 1 (2.9) 0 0
Germany (Schnurbein et al)‡ 825 500 325 0 0 0 2 (0.3) 1 (0.2) 1 (0.3) 0 0 0
United States36 367 0 0 0 367 0 3 (0.82) 0 0 0 3 (0.82) 0
Spain (Blanco et al)‡ 516 410 89 17 0 0 3 (0.6) 1 (0.24) 2 (2.2) 0 0 0
This study§ 3,429 0 0 294 3,135 2,772 14 (0.41) 0 0 4 (1.4) 10 (0.32) 2 (0.07)
Total 16,024 6,654 3,266 636 5,014 10,724 61 3 27 9 22 5
Total fully sequenced 524 4,273 4,903 9 (0.017) 18 (0.004) 3 (0.0006)
RAD51D
United Kingdom20 1,648 737 911 0 0 1,060 0 8 (0.88) 0 0 1 (0.09)
Canada and Belgium (Osher
et al) 175 0 175 0 0 0 1 (0.57) 0 1 (0.57) 0 0 0
Finland (Pelttari et al) 2,200 95  297 541† 1,287† 2 3 (0.55) 0
United Kingdom40 1,305 741 303 16 245 466 2 0 0 0 2 (0.82) 0
Spain (Gutierrez-Enriquez
et al) 713 171 491 51 4 (0.81)
United States36 367 0 0 0 367 0 4 0 0 0 4 (1.1) 0
This study§ 3,429 0 0 294 3,135 2,772 1 (0.34) 11 (0.35) 1 (0.036)
Total fully sequenced 361 3,747 4,298 5 (1.4) 17 (0.45) 2 (0.046)
Abbreviations: BC, breast cancer case proband from breast cancer familial study; BC/OC, breast and/or ovarian cancer proband from breast and/or ovarian cancer
family; NS, not specified; OC, ovarian cancer proband from ovarian cancer family; uOC, ovarian cancer cases not selected based on family history.
Unaffected controls.
†The subset was not fully sequenced but underwent genotyping for mutations detected previously.
‡RAD51C study references: Zheng et al: Breast Cancer Res Treat 124:857-861, 2010; Akbari et al: Breast Cancer Res 12:404, 2010; Clague et al: PLoS One
6:e25632, 2011; De Leeneer et al: Breast Cancer Res Treat 133:393-398, 2012; Lu et al: Fam Cancer 11:381-385, 2012; Coulet et al: Clin Genet 83:332-336, 2013;
Schnurbein et al: Breast Cancer Res 15:R120, 2013; Blanco et al: Breast Cancer Res Treat 147:133-143, 2014.
§In the United States, United Kingdom, Australia, Denmark, and Poland.
RAD51D study references: Osher et al: Br J Cancer 106:1460-3, 2012; Pelttari et al: J Med Genet 49:429-432, 2012; Gutierrez-Enriquez et al: Int J Cancer
134:2088-2097, 2014.
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